AL-S Pharma Appoints Harry Welten as CEO
Harry Welten succeeds Michael Salzmann and will lead AP-101 toward a confirmatory Phase 3 ALS trial targeted to start in 2027.
Related stories
FedEx Freight Shares Surge 14% After Quarterly Beat and Strong Profit Outlook
Shares rose 14% in early trading Friday after FedEx Freight forecast fourth-quarter profit above analyst estimates. Analysts backed the trucking firm's 2027 growth expectations.
M impact | EQUITY | Oct 30, 2026, 03:02 PM UTC
AstraZeneca Launches $1.5 Billion Cost-Savings Program
AstraZeneca said it is launching the program to free up resources for investment in its drug pipeline.
M impact | EQUITY | Oct 30, 2026, 02:58 PM UTC
Nasdaq Slides More Than 2%, S&P 500 Falls More Than 1%
The Nasdaq fell more than 2%, while the S&P 500 declined more than 1%; the Dow also dipped. Employment cost growth cooled in Q3.
M impact | EQUITY | Oct 30, 2026, 02:57 PM UTC
S&P 500 Energy Index Hits Record High as Oil Rallies
The S&P 500 energy index hit a record high as an oil rally lifted the sector.
M impact | EQUITY | Oct 30, 2026, 02:57 PM UTC
TSX Falls 1.57% as Gold Slump and Tech Weakness Weigh
Canada’s S&P/TSX Composite Index was down 1.57% at 35,673.99 points as of 10:33 a.m. ET, after hitting a one-week low. Mining and technology stocks declined.
M impact | EQUITY | Oct 30, 2026, 02:52 PM UTC
Regeneron shares rise 11.3% to nearly two-year high after quarterly results exceed expectations
Regeneron shares rose 11.3% to 91, reaching a nearly two-year high after quarterly results exceeded expectations.
M impact | EQUITY | Oct 30, 2026, 02:51 PM UTC